Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT07361354
PHASE1
An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
Sponsor: Angitia Incorporated Limited
View on ClinicalTrials.gov
Summary
This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
Official title: A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of AGA2118 in Healthy Japanese, Chinese, and Caucasian Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2026-01-05
Completion Date
2026-09
Last Updated
2026-07-08
Healthy Volunteers
Yes
Interventions
DRUG
AGA2118
Participants will receive AGA2118 administered by subcutaneous injection
Locations (1)
Los Angeles EPCU
Glendale, California, United States